Retinoblastoma is a rare cancer that begins in the retina, or the sensitive lining in the back of your eye. While it can affect people of all ages, it is…
In a February 8, 2022 news release, late-stage clinical company Synthetic Biologics, Inc. shared that the FDA granted Orphan Drug designation to the therapeutic candidate VCN-01. VCN-01 is a therapeutic…
When many people hear CAR T-cell therapy, they think about a treatment designed to address cancer. Recently, a new study done on mice models has suggested that an experimental form…
According to a story from globenewswire.com, the biopharmaceutical company Innovation Pharmaceuticals recently released a report in which recent studies and pre-clinical research has suggested that the company's experimental drug Kevetrin…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
